Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Tebentafusp-tebn for metastatic uveal melanoma - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Drug: Tebentafusp-tebn for metastatic uveal melanoma

New Drug: Tebentafusp-tebn for metastatic uveal melanoma
  • Open-label Phase III trial
  • Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma
  • Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine
  • Median OS: 21.7 vs. 16.0 months (HR: 0.51 [95% Cl, 0.37-0.71])
  • Median PFS: 3.3 vs. 2.9 months (HR: 0.73 [95% Cl, 0.58-0.94])
  • 1-year OS: 73% vs. 59% (HR: 0.51 [0.37-0.71] P<0.001)
  • 6 months PFS: 31% vs. 19% (HR: 0.73 [0.58-0.94], P=0.01)
  • Any grade AEs: cytokine release syndrome (89% vs. 3%), rash (83% vs. 24), pyrexia (76% vs. 3%), pruritus (69% vs. 21%), chills (47% vs. 3%), nausea (43% vs. 19%), fatigue (41% vs.26%), hypotension (38% vs 0%)

N Engl J Med 2021; 385:1196-1206

Nathan P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma


Reviewed by Hasan Cagri Yildirim, MD on Sep 30, 2021

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More